Antiviral therapy of acute respiratory infections in children during coronavirus pandemic: a review of studies and clinical experience
In the beginning of summer 2020, were observed some positive trends in the incidence of SARS-CoV-2 worldwide, which made it possible to ease quarantine measures in several countries. This inevitably increases contacts between children of different ages and the incidence of various acute respiratory infections. Considering non-specific clinical manifestations of COVID-19 in children, the prevalence of mild and moderate forms in the pediatric population, and difficulties associated with differential diagnosis between respiratory monoinfections and mixed infecions during the pandemic, it is necessary to use direct action antiviral drugs from the first days of the disease. This review focuses on antiviral effects of umifenovir evaluated in preclinical and clinical trials and the possibility of its use in children aged 2 years and older.